{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:16:48Z","timestamp":1761005808212,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","strokejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2016.12.037","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T11:30:37Z","timestamp":1492169437000},"page":"e102-e104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9664-5433","authenticated-orcid":false,"given":"David","family":"Bissig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Manjunath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany R.","family":"Traylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0010","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40262-016-0417-0","article-title":"Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study","volume":"56","author":"Glund","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0025","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.005","article-title":"Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists","volume":"22","author":"Rybinnik","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0030","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.11.013","article-title":"Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke","volume":"23","author":"Kate","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0035","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/STROKEAHA.116.013550","article-title":"Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab","volume":"47","author":"Berrouschot","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0040","doi-asserted-by":"crossref","first-page":"A12509","DOI":"10.1161\/circ.132.suppl_3.12509","article-title":"Abstract 12509: initial reports on the safety of intravenous tissue plasminogen activator in acute ischemic stroke patients taking novel oral anticoagulants (NOACs)","volume":"132","author":"Xian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.037_bib0045","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.07.021","article-title":"Safety of intravenous thrombolysis among stroke patients taking new oral anticoagulants \u2013 case series and systematic review of reported cases","volume":"24","author":"Shahjouei","year":"2015","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717300794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717300794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:39:42Z","timestamp":1760942382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305717300794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1052305717300794"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2016.12.037","relation":{},"ISSN":["1052-3057"],"issn-type":[{"type":"print","value":"1052-3057"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator","name":"articletitle","label":"Article Title"},{"value":"Journal of Stroke and Cerebrovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2016.12.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}